...
首页> 外文期刊>Clinical and experimental nephrology >Diagnosis and therapy of atheromatous renal artery stenosis
【24h】

Diagnosis and therapy of atheromatous renal artery stenosis

机译:动脉粥样硬化性肾动脉狭窄的诊断和治疗

获取原文
获取原文并翻译 | 示例

摘要

Atheromatous renal artery stenosis (ARAS), a lesion of systemic atherosclerotic disease, is the leading cause of stenotic lesions in the renal artery, followed by fibromuscular dysplasia, a primary abnormality of the renal artery. As a result of several clinical trails, which failed to show an additional benefit of renal revascularization to medical therapy in ARAS, the treatment of ARAS has shifted, and renal revascularization is less commonly performed for ARAS. However, it is recognized that renal revascularization benefits some patients with ARAS. Advances in imaging modalities would allow more frequent detection of ARAS in a society with a growing elderly population, a group with an increased prevalence of systemic atherosclerotic disease. Therefore, it is imperative to identify the patients with ARAS who could benefit from renal revascularization. This review presents a strategy for the treatment of ARAS based on the results of our analysis.
机译:动脉粥样硬化性肾动脉狭窄(ARAS)是一种系统性动脉粥样硬化性疾病,是肾动脉狭窄病变的主要原因,其次是纤维性肌发育异常,这是肾动脉的主要异常。由于一些临床试验的结果,这些试验未能显示出肾脏血运重建对ARAS的药物治疗具有额外的益处,因此ARAS的治疗发生了变化,肾脏血运重建对于ARAS的应用较少。但是,已经认识到肾血管重建有益于一些ARAS患者。成像方式的进步将使得在老年人口不断增加的社会(系统性动脉粥样硬化疾病患病率上升)的人群中更频繁地检测ARAS。因此,必须确定可以从肾脏血管重建中受益的ARAS患者。这篇综述基于我们的分析结果提出了一种治疗ARAS的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号